SBL
PACB icon

Sargent Bickham Lagudis’s Pacific Biosciences PACB Stock Holding History

Sargent Bickham Lagudis’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-225
Closed -$2K – 1109
2022
Q1 		$2K Buy
225
+35
+18% +$403 ﹤0.01% 895
2021
Q4 		$4K Hold
190
– – ﹤0.01% 832
2021
Q3 		$5K Hold
190
– – ﹤0.01% 811
2021
Q2 		$7K Buy
+190
New +$5.53K ﹤0.01% 766

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Sargent Bickham Lagudis's PACB Position: Q2 2022 in Review

Sargent Bickham Lagudis sold out of Pacific Biosciences (PACB) in Q2 2022, closing a stake of 225 shares — an estimated $2K sold.

Sargent Bickham Lagudis first reported a position in PACB in Q2 2021 and held it in 4 quarters. The position peaked at $7K in Q2 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q2 2022.

  • Sargent Bickham Lagudis reported no remaining Pacific Biosciences position as of Q2 2022 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 225 Pacific Biosciences shares in Q2 2022, an estimated $2K.
  • Sargent Bickham Lagudis first reported a position in Pacific Biosciences in Q2 2021 and held it in 4 quarters.
  • Sargent Bickham Lagudis's Pacific Biosciences position peaked at $7K in Q2 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q2 2022, filed 13 Jul 2022.